GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Inventory Turnover

MYGN (Myriad Genetics) Inventory Turnover : 2.43 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Myriad Genetics's Cost of Goods Sold for the three months ended in Sep. 2024 was $63.5 Mil. Myriad Genetics's Average Total Inventories for the quarter that ended in Sep. 2024 was $26.2 Mil. Myriad Genetics's Inventory Turnover for the quarter that ended in Sep. 2024 was 2.43.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Myriad Genetics's Days Inventory for the three months ended in Sep. 2024 was 37.58.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Myriad Genetics's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.12.


Myriad Genetics Inventory Turnover Historical Data

The historical data trend for Myriad Genetics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Inventory Turnover Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 6.15 8.90 11.41 11.22

Myriad Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.42 2.62 2.77 2.54 2.43

Myriad Genetics Inventory Turnover Calculation

Myriad Genetics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=236.2 / ((20.1 + 22) / 2 )
=236.2 / 21.05
=11.22

Myriad Genetics's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover (Q: Sep. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Sep. 2024 ) / ((Total Inventories (Q: Jun. 2024 ) + Total Inventories (Q: Sep. 2024 )) / count )
=63.5 / ((26.1 + 26.2) / 2 )
=63.5 / 26.15
=2.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myriad Genetics  (NAS:MYGN) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Myriad Genetics's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=26.15/63.5*365 / 4
=37.58

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Myriad Genetics's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=26.15 / 213.3
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Myriad Genetics Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Paul J Diaz director, officer: President and CEO 680 SOUTH FOURTH STREET, LOUISVILLE KY 40202
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Reitan Colleen F director 300 THIRD STREET, CAMBRIDGE MA 02142
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116